Registration
Sign Up:
Impact of SARS-CoV-2 variants and mutations on COVID-19 diagnostics
February 16, 2022 [ 11AM (Buenos Aires - ART), 3PM (Milan - CEST), 9AM (US EDT)]
SARS-CoV-2 has undergone a broad process of recombination since identification of the prototype strain in 2019, introducing a huge number of mutations in its genome and generating a vast array of variants of interest (VoI) and concern (VoC). Many of such variants developed several mutations in Spike protein and RBD, with the new Omicron (B.1.1.529) strain displaying over 30 changes, 15 of which concentrated in the RBD. Besides their impact on virus biology, as well as on the risk of detection failure with some molecular techniques (i.e. S gene dropout), recent evidence suggests that these mutations may also jeopardize the reliability of currently available commercial immunoassays for detecting anti-SARS-CoV-2 antibodies.
Click here to convert to your time-zone.
Presenters:
Prof. Khosrow Adeli
President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)Professor of Clinical Biochemistry at the Hospital for Sick Children, University of Toronto, Canada
Prof. Giuseppe Lippi [Chair]
Professor of Clinical Biochemistry & Director of Laboratory Medicine Service, University Hospital of Verona.President, School of Medicine, University of Verona, Italy
Dr. Brandon M. Henry
Disease Intervention & Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA & Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA